Please login to the form below

Not currently logged in
Email:
Password:

Michael Cola resigns as president of Shire Specialty Pharmaceuticals

Leaves to "explore new career opportunities and challenges”

Michael Cola - ShireShire's Michael Cola is to resign as president of the company's specialty pharmaceuticals business.

“With the company in a position of tremendous strength it is time for me to explore new career opportunities and challenges,” he said. “It has been an honour to work with my colleagues at Shire.”

Cola had been with Shire for seven years, joining as executive VP and general manager for the company's global therapeutic business units.

He assumed the role of president of the specialty pharmaceuticals business in 2006.

His role will be taken over by the company's CEO Angus Russell while the search for a new president is carried out.

Russell said: “As president of the SP business, Mike was instrumental in helping Shire transform itself from a company dominated by a single product in one market to a leading global biopharmaceutical company with a diversified product portfolio.”

Prior to joining Shire, Cola held several executive positions at pharma companies, including Merck,  AstraZeneca and Safeguard Scientifics.

3rd April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Harnessing complexity
Companion diagnostics in oncology...
"Not Another Boring Survey?"
Winning over HCPs… How to Increase Participant Engagement in Healthcare Market Research...
What pharma needs to know about genomic data in 2016
Consultant David Cooney from Blue Latitude Health talks us through what this progress in genomics means for pharma in 2016....

Infographics